NCT00343551View on ClinicalTrials.gov

Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension.

PHASE3CompletedINTERVENTIONAL
Enrollment

654

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

January 31, 2007

Conditions
Essential Hypertension
Interventions
DRUG

Aliskiren

Trial Locations (2)

Unknown

Investigative Centers

Novartis Pharmaceuticals, Basel

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY

NCT00343551 - Efficacy and Safety of Aliskiren 300mg Compared to Irbesartan 300mg and Ramipril 10 mg in the Setting of a Missed Dose for Patients With Essential Hypertension. | Biotech Hunter | Biotech Hunter